NAVIDEA BIOPHARMACEUTICALS, INC.: 10-Q filed 2023-05-11

Name: NAVIDEA BIOPHARMACEUTICALS, INC.: 10-Q filed 2023-05-11
Creator: NAVIDEA BIOPHARMACEUTICALS, INC.
License: https://creativecommons.org/licenses/by/4.0/

What NAVIDEA BIOPHARMACEUTICALS, INC. reported in its quarterly report filed 2023-05-11 (fiscal Q1 2023): 39 published measures, 79 facts as tagged in accession 0001437749-23-013972.

This filing

Form: 10-Q (quarterly report)
Filed: 2023-05-11
Fiscal period: fiscal Q1 2023
Accession: 0001437749-23-013972 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All NAVIDEA BIOPHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2023-03-31	2,367,586	USD
At 2022-12-31	4,371,606	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2023-03-31	11,915,209	USD
At 2022-12-31	12,514,916	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2023-03-31	-9,840,140	USD
At 2022-12-31	-8,435,828	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2023-03-31	33,795	USD
At 2022-12-31	1,995,860	USD

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-1,722,117	USD	90
2022-01-01 to 2022-03-31	-2,556,106	USD	90

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	15,068	USD	90
2022-01-01 to 2022-03-31	42,017	USD	90

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-200,539	USD	90
2022-01-01 to 2022-03-31	-339,453	USD	90

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-39,409	USD	90
2022-01-01 to 2022-03-31	-118,192	USD	90

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2023-03-31	-389,478,978	USD
At 2022-12-31	-388,002,649	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	32,654,012	shares	90
2022-01-01 to 2022-03-31	30,207,746	shares	90

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-0.05	USD/shares	90
2022-01-01 to 2022-03-31	-0.1	USD/shares	90

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2023-03-31	136,421	USD
At 2022-12-31	135,347	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	19,669	USD	90
2022-01-01 to 2022-03-31	184,850	USD	90

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-2,422,369	USD	90
2022-01-01 to 2022-03-31	-2,979,284	USD	90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2023-03-31	1,197,534	USD
At 2022-12-31	3,203,944	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2023-03-31	9,250,417	USD
At 2022-12-31	9,941,889	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2023-03-31	3,171,126	USD
At 2022-12-31	2,122,538	USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

Period	Value	Unit	Days
At 2023-03-31	1,010,552	USD
At 2022-12-31	1,000,241	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	2,422,369	USD	90
2022-01-01 to 2022-03-31	2,979,284	USD	90

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

Period	Value	Unit	Days
At 2023-03-31	460,636	USD
At 2022-12-31	427,344	USD

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	1,154,916	USD	90
2022-01-01 to 2022-03-31	1,810,030	USD	90

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	1,267,453	USD	90
2022-01-01 to 2022-03-31	1,169,254	USD	90

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2023-03-31	32,851,252	shares
At 2022-12-31	32,687,666	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2023-03-31	379,414,977	USD
At 2022-12-31	379,343,124	USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

Period	Value	Unit
At 2023-03-31	-9,547,623	USD
At 2022-12-31	-8,143,310	USD
At 2022-03-31	-2,109,442	USD
At 2021-12-31	624,743	USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

Period	Value	Unit	Days
At 2023-03-31	11,305	USD
At 2022-12-31	20,300	USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

Period	Value	Unit	Days
At 2023-03-31	11,298	USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

Period	Value	Unit	Days
At 2023-03-31	734,870	USD
At 2022-12-31	835,845	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2023-03-31	598,449	USD
At 2022-12-31	700,498	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2023-03-31	11,774	USD
At 2022-12-31	11,774	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2023-03-31	672,060	USD
At 2022-12-31	780,110	USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-1,476,330	USD	90
2022-01-01 to 2022-03-31	-2,987,245	USD	90

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-1,476,329	USD	90
2022-01-01 to 2022-03-31	-2,987,242	USD	90

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	27,555	USD	90
2022-01-01 to 2022-03-31	22,878	USD	90

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-17,198	USD	90
2022-01-01 to 2022-03-31	-4,299	USD	90

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	117,810	USD	90
2022-01-01 to 2022-03-31	3,712	USD	90

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	9,443	USD	90
2022-01-01 to 2022-03-31	93,889	USD	90

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	33,292	USD	90
2022-01-01 to 2022-03-31	171,837	USD	90

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	1,048,588	USD	90
2022-01-01 to 2022-03-31	143,616	USD	90

Inspect the source

Entity: NAVIDEA BIOPHARMACEUTICALS, INC. / CIK 0000810509
Captured: 2026-09-22 19:30 UTC
SEC response SHA-256: e6e15b291454205779be87d7d17e86894a378fd299b7dd1312591814ed2d7c83

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000810509.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))